Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site

Journal of Clinical Oncology

Volumn 18, Issue 3, 2000, Pages 632-635

  Hainsworth, John D ^a   Lennington, Wayne J ^a   Greco, F Anthony ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; ONCOPROTEIN; TRASTUZUMAB; VINBLASTINE;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ARTICLE; CARCINOMA; CELL DIFFERENTIATION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOPEROXIDASE STAINING; LIVER CARCINOMA; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM TUMOR; ONCOGENE NEU; PRIORITY JOURNAL; RETROPERITONEAL TUMOR; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 0033966154     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.3.632     Document Type: Article

References (21)

1. Coussens L, Yang-Feng TL, Liao YC, et al: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu-oncogene. Science 230:1132-1139, 1985
2. Slamon DJ, Godophin W, Jones LA, et al: Studies of the Her-2 proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
3. Varley JM, Swallow JE, Brammar WJ, et al: Alternatives to either c-erb2 (neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene 1:423-430, 1987
4. Paik S, Hazan R, Fisher ER, et al: Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of c-erbB2 protein overexpression in primary breast cancer. J Clin Oncol 8:103-112, 1990
5. Allred DC, Clark GM, Tandon AK, et al: HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10:599-605, 1992
6. Weiner DB, Nordberg J, Robinson R, et al: Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinoma of the lung. Cancer Res 50:421-432, 1990
7. Sun XF, Carstensen JM, Nordenskjold B: Expression of c-erbB-2 and p53 in colorectal adenocarcinoma. Ann Cell Pathol 8:203-211, 1995
8. Cobleigh MA, Vogel CL, Tripathy D, et al: Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 17:97a, 1998 (abstr 376)
9. Slamon D, Leyland-Jones B, Shak S, et al: Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: A randomized, multinational controlled phase III trial. Proc Am Soc Clin Oncol 17:98a, 1998 (abstr 377)
10. Nystrom JS, Weiner JM, Wolf RM, et al: Metastatic and histologic presentations in unknown primary cancer. Semin Oncol 4:53-68, 1977
11. Hainsworth JD, Johnson DH, Greco FA: Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: Results of a 12-year experience at a single institution. J Clin Oncol 10:912-922, 1992
12. Einhorn LH, Donohue JD: Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87:293-301, 1977
13. Williams SD, Birch R, Einhorn LH, et al: Treatment of disseminated germ cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316:1435-1440, 1987
14. Greco FA, Hainsworth JD: Cancer of unknown primary site, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Philadelphia, PA, Lippincott-Raven Publishers, 1997, pp 2423-2443
15. Ellerbroek N, Holmes F, Singletary E, et al: Treatment of patients with isolated axillary nodal metastases from an occult primary carcinoma consistent with breast origin. Cancer 66:1481-1491, 1990
16. Eltabbakh GH, Piver MS: Extraovarian primary peritoneal carcinoma. Oncology 12:813-819, 1998
17. Greco FA, Vaughn WK, Hainsworth JD: Advanced poorly differentiated carcinoma of unknown primary site: Recognition of a treatable syndrome. Ann Intern Med 104:547-551, 1986
18. Goldberg RM, Smith FP, Ueno W, et al: 5-Fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary. J Clin Oncol 4:395-399, 1986
19. Milliken ST, Tattersall MH, Woods RL, et al: Metastatic adenocarcinoma of unknown primary site: A randomized study of two combination chemotherapy regimens. Eur J Cancer Clin Oncol 23: 1645-1653, 1987
20. Lenzi R, Raber MN, Frost P, et al: Phase II study of cisplatin, 5-FU, and folinic acid in patients with tumors of unknown primary origin. Eur J Cancer 29A:1634-1638, 1993
21. Hainsworth JD, Erland JB, Kalman LA, et al: Carcinoma of unknown primary site: Treatment with one-hour paclitaxel, carboplatin, and extended schedule etoposide. J Clin Oncol 15:2385-2394, 1997.